Beta Bionics, Inc.
BBNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$793.17M
Close$
Share Statistics
| Market cap | $793.17 Million |
|---|---|
| Enterprise Value | $757.25 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.81 |
| Beta | 3.38 |
| Outstanding Shares | 44,545,293 |
Return
| Return on Equity | -28.46% |
|---|---|
| Return on Assets | -24.96% |
| Return on Invested Capital | -28.21% |
Valuation & Multiples
| P/E Ratio | -10.49 |
|---|---|
| PEG | -27.09 |
| Price to Sales | 8.66 |
| Price to Book Ratio | 3.46 |
| Enterprise Value to Revenue | 6.36 |
| Enterprise Value to EBIT | -10.08 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$31.46 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
$34.72 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 108.54% |
|---|---|
| Total Invested | $67,088▼ 99.99% |
| Investors Holding | 9▼ 129.00% |
ESG Score
No data
About Beta Bionics, Inc.
422 employees
CEO: Sean T. Saint Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The...